The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

Launched by ANHUI MEDICAL UNIVERSITY · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called repetitive transcranial magnetic stimulation (rTMS) to see if it can help improve the motor symptoms of Parkinson's disease. rTMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. Previous smaller studies have suggested that this treatment may help reduce symptoms and slow down the progression of Parkinson's disease. The research team is conducting this study across multiple centers in the country to gather more evidence about its effectiveness.

To participate in this trial, you need to be at least 40 years old and have a diagnosis of idiopathic Parkinson's disease. You should also be able to complete tests and cooperate with the rTMS treatment. However, certain conditions may exclude you from participating, such as having severe brain injuries, other types of Parkinson's, or specific medical implants like pacemakers. Participants will receive either the rTMS treatment or a placebo (a treatment that looks the same but has no active effect) without knowing which one they are receiving. This helps researchers understand how well the treatment works. Overall, this trial aims to provide important insights into a potentially beneficial therapy for people living with Parkinson's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 40 years old;
• • 2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\[1\];
• • 3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
• • 4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
• • 5. MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
• Exclusion Criteria:
• • 1. Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
• • 2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
• • 3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
• • 4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
• • 5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
• • 6. Diagnosed with a neuropsychiatric disorder other than PD
• • 7. Have a history of drug abuse or drug use;
• • 8. Participants in any clinical trial within the previous 6 month;
• • 9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months;
• • 10. Other conditions deemed unsuitable for inclusion by the investigator.